{"entity":{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.","summary":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer. ClinicalTrials.gov record last updated 2025-09-17: recruiting. Enrollment is planned at 180 participants. Primary completion is estimated at 2027-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin, Pembrolizumab. Registered primary measures: Objetctive Response Rate (ORR).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06942234","url":"https://clinicaltrials.gov/study/NCT06942234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["jskn016","capecitabine","eribulin","pembrolizumab"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-09-17: recruiting. Enrollment is planned at 180 participants. Primary completion is estimated at 2027-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06942234","phase":"1/2","setting":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","participation":[{"nct":"NCT06942234","source":"https://clinicaltrials.gov/study/NCT06942234","fetchedAt":"2026-10-07T16:55:18.467Z","studySha256":"3c8f7c74f79e824f005808a13b62a9ec0195f2cb5dff1be810195b2f171330d8","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-17","leadSponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-06-01","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06942234/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}